Rockwell Medical (NASDAQ:RMTI) Receives Buy Rating from HC Wainwright

Rockwell Medical (NASDAQ:RMTI)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 236.54% from the company’s current price.

RMTI has been the subject of several other research reports. StockNews.com lowered Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday. Rodman & Renshaw began coverage on Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 price target for the company. Finally, RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th.

Rockwell Medical Stock Performance

Rockwell Medical stock opened at $2.08 on Monday. Rockwell Medical has a 1-year low of $1.16 and a 1-year high of $5.15. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $67.22 million, a PE ratio of -41.60 and a beta of 1.38. The firm’s 50 day simple moving average is $2.89 and its 200 day simple moving average is $2.71.

Institutional Trading of Rockwell Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd lifted its holdings in shares of Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after acquiring an additional 8,922 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in Rockwell Medical in the 3rd quarter worth $40,000. Verus Capital Partners LLC bought a new stake in Rockwell Medical in the third quarter worth $51,000. State Street Corp grew its stake in shares of Rockwell Medical by 21.5% during the third quarter. State Street Corp now owns 95,004 shares of the company’s stock valued at $377,000 after buying an additional 16,800 shares during the last quarter. Finally, Barclays PLC purchased a new position in shares of Rockwell Medical in the third quarter worth about $90,000. Hedge funds and other institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.